跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
Health Canada
/
VYEPTI
Authorized
STANDARD
VYEPTI
Lundbeck Canada Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
29cbe5c3e8ea2cce
Company
Lundbeck Canada Inc
Type
Standard
Approval Details
Approval Id
29cbe5c3e8ea2cce
Drug Approval Canada Name
VYEPTI
Product Name
VYEPTI
Status
Marketed
Status Date
2022-08-17
Original Market Date
2022-08-17
Din
02510839
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intravenous
Schedule
Prescription , Schedule D
Ahfs
28:32.12
Atc Original
N02CD05 EPTINEZUMAB
Atc Name
n 02 cd 05
Aig Number
0162703001
Company Name
Lundbeck Canada Inc
Company Address
2600 Alfred-Nobel, Suite 400, St-Laurent, Quebec, Canada, H4S 0A9
Company Detail Path
/organization/lundbeck-canada-inc
Company Information
Pharmaceutical Company Name
Lundbeck Canada Inc
Country Name
Canada
Province Name
Quebec
City Name
montréal,quebec,country_ca
Address
2600 boul Alfred-Nobel bureau 400
Active Ingredients
EPTINEZUMAB
100 MG / ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
29cbe5c3e8ea2cce
Type
Standard
Back to Health Canada Approvals
VYEPTI - Health Canada Drug Approval Details